PGEN
Precigen, Inc.3.8700
+0.0600+1.57%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A bolsters launch mechanics
Q&A largely reaffirmed Papzimia's explosive launch, adding operational color on patient flows without contradictions to prepared remarks. Management clarified the hub captures only part of demand—patients also flow from institutional hubs—with conversions hinging on IDN activation and weeks-long prior auths, soon eased by April's permanent J-code. Little stocking occurs amid vial-by-vial orders; patients advance to second doses fluidly. Community prescribers surprised positively via logistics aids; payer mix skews 60-65% commercial with high-teens gross-to-net. EMA review progresses amid EU enthusiasm. Bulls eye Q2 acceleration.
Key Stats
Market Cap
1.37BP/E (TTM)
-Basic EPS (TTM)
-1.42Dividend Yield
0%Recent Filings
8-K
PAPZIMEOS launches post-FDA nod
Precigen reported Q3 2025 results, highlighting PAPZIMEOS's FDA approval in August and rapid US launch as the first RRP therapy, with over 100 patients registered and 90% of target institutions engaged. Cash hit $123.6M, bolstered by a $100M credit tranche, funding to break-even; revenues rose $2.0M while SG&A surged 144% on launch costs. EMA filing submitted November. Non-cash items drove $325.3M net loss.
10-Q
Q3 FY2025 results
Precigen tripled Q3 revenues to $2.9M versus Q3 2024, fueled by $1.8M from a terminated collaboration while product and service lines grew modestly from Exemplar. Operating loss widened to $34.5M from $21.3M on higher SG&A for Papzimeos commercialization, yet R&D dipped post-approval. Net loss ballooned to $146.3M, driven by $111.5M warrant fair-value hit and $179.0M preferred conversion dividend; EPS fell to $(1.06) on 307M shares. Cash dipped to $14.3M with $109.3M investments, bolstered by $92.9M term debt (SOFR+6.5%, due 2030, covenants met). FDA approved Papzimeos in August 2025. Debt covenants curb flexibility.
8-K
Preferred stock conversion completed
Precigen holders converted 79,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock, valued at $79,000,000, into 54,937,411 common shares on September 15, 2025, with delivery on September 17. This exchange, exempt under Section 3(a)(9) of the Securities Act, simplifies the capital structure by eliminating preferred obligations. No cash changed hands. Yet dilution hits common shareholders hard.
8-K
Precigen announces $125M non-dilutive financing to bolster commercialization of PAPZIMEOS and support international expansion.
Precigen, Inc. has secured a $125 million non-dilutive financing facility from investment funds managed by Pharmakon Advisors, LP. The first tranche of $100 million was funded at closing, with an additional $25 million available at Precigen's discretion through June 29, 2027. This financing strengthens the company's balance sheet to support the commercialization of PAPZIMEOS for recurrent respiratory papillomatosis (RRP) in the US, expansion into international markets, and pursuit of pediatric and other HPV-related indications. The facility matures in five years with interest at 6.50% plus three-month SOFR (floor of 3.75%). Evercore advised Precigen, and Davis Polk & Wardwell LLP served as legal counsel.
8-K
Precigen signs Catalent supply deal
Precigen inked a three-year supply deal with Catalent on August 13, 2025, locking in exclusive external fill-and-finish for its PRGN-2012 gene therapy product across the U.S. and select territories. The pact mandates minimum batch purchases yearly, with prices rising annually to match costs like labor and utilities. This secures manufacturing capacity while binding Precigen to commitments. Risks lurk in potential breaches or regulatory snags.